Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Evercore upgrades DexCom to Outperform on strong growth and margin expansion outlook
DXCM
$72.90
+$0.17 +0.23%

Evercore upgrades DexCom to Outperform on strong growth and margin expansion outlook

Analyst Insights
24 Mar 2026
davit kirakosyan
View Source
Bullish
pluang ai news

Evercore ISI upgraded DexCom's stock rating to Outperform from In Line, setting a $90 price target based on expected double-digit revenue growth and over 200 basis points of annual margin expansion through 2028. The firm anticipates a 25% compound annual growth rate in earnings per share, driven by advancements in automated delivery, favorable coverage decisions for type 2 non-insulin-treated diabetes, and ongoing margin improvements. This upgrade reflects confidence in DexCom's growth trajectory and operational leverage, valuing the company at about 29.5 times 2027 earnings and 19.8 times EBITDA.

More News (DXCM)

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App